NASDAQ: RAPP - Rapport Therapeutics, Inc.

Yield per half year: -44.71%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Rapport Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

more details
The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2024-06-07
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.rapportrx.com
Цена ао 10.02
Change price per day: 0% (10.51)
Change price per week: +27.09% (8.27)
Change price per month: -33.35% (15.77)
Change price per 3 month: -43.37% (18.56)
Change price per half year: -44.71% (19.01)
Change price per year: 0% (10.51)
Change price per 3 year: 0% (10.51)
Change price per 5 year: 0% (10.51)
Change price per 10 year: 0% (10.51)
Change price per year to date: -41.71% (18.03)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 1.89 10
Total: 3.75

Efficiency

Title Value Grade
ROA, % -22.38 0
ROE, % -24.68 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0595 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 234.85 10
Yield EPS, % -27.32 0
Total: 6
More

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Neuroscience and Healthcare ETF 0.71137 19.72 0.03
iShares Micro-Cap ETF 0.04983 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00794 38.04 0.6026
0.2624.950.72



Head Job title Payment Year of birth
Dr. Steven M. Paul M.D. Founder & Independent Chairman 1951 (74 years)
Mr. Abraham N. Ceesay M.B.A. CEO, President, Treasurer & Director 1978 (47 years)
Dr. Troy A. Ignelzi Chief Financial Officer 1968 (57 years)
Ms. Cheryl Gault Chief Operating Officer 1979 (46 years)
Mr. David Bredt M.D., Ph.D. Founder & Chief Scientific Officer 1965 (60 years)
Ms. Karina Chmielewski Chief Information Officer & Head of Operations
Ms. Julie DiCarlo Head of Communications & Investor Relations
Ms. Kathleen A. Wilkinson Chief People Officer 1972 (53 years)
Dr. Bradley S. Galer M.D. Chief Medical Officer 1962 (63 years)
Mr. Swamy Yeleswaram Ph.D. Chief Development Officer 1963 (62 years)

Address: United States, Boston, 1325 Boylston Street - open in Google maps, open in Yandex maps
Website: https://www.rapportrx.com